EGRX News and Press, Eagle Pharmaceuticals Inc. From 08/22/23

WOODCLIFF LAKE, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the following healthcar...

2023-08-17 07:02:06 ET Eagle Pharmaceuticals Inc ( NASDAQ: EGRX ) Thursday reiterated its previously issued guidance for the 2023 fiscal year. Says full-year 2023 adjusted non-GAAP EBITDA is expected to range from $78.0 to $84.0 million and adjusted non-GAAP earnings per share...

-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million 1 -- -- FY 2023 Adjusted non-GAAP earnings per share expected to be $4.40 - $4.70 1 -- -- Reflects strength of Eagle’s business and product pipeline; Company poised for sustained long-term growth -- WO...

2023-08-09 14:31:20 ET Piper Sandler has downgraded Eagle Pharmaceuticals ( NASDAQ: EGRX ) to underweight, citing concerns about the declining contribution of bendamustine products in the longer term. The investment bank said that Eagle was facing "challenging dynamics," includi...

2023-08-08 12:57:14 ET Eagle Pharmaceuticals, Inc. (EGRX) Q2 2023 Earnings Conference Call August 8, 2023, 08:30 AM ET Company Participants Lisa Wilson - IR Scott Tarriff - President and CEO Brian Cahill - CFO Conference Call Participants Tim Lugo - W...

2023-08-08 06:54:55 ET Eagle Pharmaceuticals press release ( NASDAQ: EGRX ): Q2 Non-GAAP EPS of $1.18 beats by $0.04 . Revenue of $64.6M (-12.8% Y/Y) beats by $5.24M . For further details see: Eagle Pharmaceuticals Non-GAAP EPS of $1.18 beats by $0.04, re...

• Total revenue for Q2 2023 was $64.6 million • Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income 1 was $1.18 per basic and diluted share • Q2 2023 net income was $5.2 million • Q2 2023 adjusted non...

2023-08-07 14:31:02 ET Eagle Pharmaceuticals ( NASDAQ: EGRX ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is $1.14 (-26.9% Y/Y) and the consensus Revenue Estimate is $59.36M (-19.9% Y/Y). Over the ...

2023-08-03 14:13:02 ET Summary Today, we are circling back on Eagle Pharmaceuticals for the first time in a while as the shares are down big since the start of 2022. The company is managing to stay profitable as it manages through a period of sales declines. Management did jus...

WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its second quarter 2023 financial results on Tuesday, August 8, 2023, before the market opens. ...